Shire white paper outlines new treatment framework for ADHD

Shire has presented an expert white paper calling for new approaches to tackling the impact of attention deficit hyperactivity disorder (ADHD) on a broad scale.

The paper – ADHD: Making the Invisible Visible – was initiated, facilitated and funded by Shire with the support of the European Brain Council and the EU branch of the Global Alliance of Mental Illness Advocacy Networks.

It noted that ADHD affects one in 20 children and adolescents in Europe, with the condition often leading to greater peer rejection, fewer close friendships and poorer academic performance, which can develop into difficulties finding employment.

As such, the white paper recommended a series of measures to tackle the issue, including improving awareness of ADHD, ensuring it is diagnosed earlier, broadening access to treatment and encouraging a patient-centric research agenda.

Dr Mary Baker, president of the European Brain Council, said: "There is potential for people with ADHD to lead fulfilled and successful lives. We want to give everyone with ADHD this opportunity."

Shire is the developer of several ADHD therapies, including Vyvanse, Intuniv and Adderall XR.